In this paper, we investigate how the lithium dose-concentration ratio changes across the lifespan. Methods This was a cross-sectional analysis of 63 current lithium users aged 20-95 years using data from McGLIDICS (the McGill Geriatric Lithium-Induced Diabetes

Insipidus Clinical Study). Participants underwent blood and urine tests, including serum lithium concentrations. Multivariate analyses were conducted to evaluate potential correlates of the lithium dose-concentration ratio. Results We found that between the ages of 40-95 years, the total daily dose of lithium required to achieve a given serum concentration decreases threefold (500 vs. 1,500 mg for 1.0 mmol/L). Greater KU-57788 cost age, once-daily dosing, and lower renal function (estimated glomerular filtration rate) were independently associated with a lower lithium dose-concentration ratio. Conclusions The lithium dose required to achieve a given serum lithium concentration decreases threefold from middle to old age, with this trend continuing into the ninth and tenth decades of life. In order to avoid lithium toxicity in aging patients, continued serum concentration monitoring and judicious dose reduction may be required, particularly

in those patients with reduced renal function.”
“Recombinant herpes zoster (HZ) vaccines may be an alternative to the live-attenuated HZ vaccine for immunocompromised individuals. This was a phase 1/2, randomized, observer-blind, placebo-controlled study in adults with multiple myeloma, non-Hodgkin lymphoma (B-or T-cell), Hodgkin lymphoma, or acute myeloid leukemia who

had undergone Quizartinib autologous hematopoietic stem-cell transplant 50 to 70 days earlier. Subjects (N = 121) were randomized 1:1:1:1 to receive (at months 0, 1, 3) three doses of 50 mu g varicella-zoster virus glycoprotein E (gE) adjuvanted with OICR-9429 in vivo AS01(B), 3 doses of gE adjuvanted with AS01(E), 1 dose of saline followed by 2 doses of gE/AS01(B), or 3 doses of saline. One month after the last dose (6 months after transplant), frequencies of CD4(+) T cells expressing bigger than = 2 activation markers after induction with gE and anti-gE antibody concentrations were higher with all gE/AS01 regimens than with saline. Both responses persisted up to 1 year in subjects vaccinated with gE/AS01. Immune responses were higher in the gE/AS01(B) 3-dose group than in the gE/AS01(B) 2-dose group but not higher than in the gE/AS01(E) 3-dose group. One serious adverse event (pneumonia) was considered vaccine related. Both formulations and both schedules were immunogenic and well tolerated in this population. This study was registered at www.clinicaltrials.gov as #NCT00920218.”
“The aim of the study was to test the validity of a French language version of the Non-Communicating Children’s Pain Checklist – Postoperative Version (NCCPC-PV): grille d’,valuation de la douleur-d,ficience intellectuelle (GED-DI).